Aytu Biopharma, Inc (AYTU)

Etorro trading 970x250
Aytu Biopharma, Inc (AYTU) Logo

About Aytu Biopharma, Inc

Aytu BioScience, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel products in the field of hypogonadism (low testosterone), cough and upper respiratory symptoms, insomnia, and male infertility in the United States and internationally. The company markets Natesto, a nasal gel for the treatment of hypogonadism (low testosterone) in men; and Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension. It also offers ZolpiMist, an oral spray for the treatment of insomnia; and MiOXSYS, an in vitro diagnostic semen analysis test that is used in the measurement of static oxidation reduction potential in human semen. Aytu BioScience, Inc. is based in Englewood, Colorado. Address: 373 Inverness Parkway, Englewood, CO, United States, 80112

Aytu Biopharma, Inc News and around…

Latest news about Aytu Biopharma, Inc (AYTU) common stock and company :

Aytu BioPharma Announces Issuance of Its First Patent for AR101/Enzastaurin
16 Aug, 2022 FinancialContent

First Issued U.S. Patent Covers Methods of Treating a Broad Range of Inherited Aortic Aneurism and Related Conditions Including Vascular Ehlers-Danlos Syndrome

Aytu BioPharma Announces Closing of $10.0 Million Registered Public Offering
15 Aug, 2022 FinancialContent

ENGLEWOOD, CO / ACCESSWIRE / August 15, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the closing of its previously announced underwritten public offering of (i) 21,505,814 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 1,750,000 shares of its common stock, and (ii) accompanying warrants (the "Common Warrants") to purchase 23,255,814 shares of its common stock (the "Offering"), resulting in gross proceeds of $10.0 million, assuming none of the accompanying Common Warrants issued in the Offering are exercised.

Stocks That Hit 52-Week Lows On Wednesday
10 Aug, 2022 FinancialContent

During Wednesday, 52 stocks hit new 52-week lows. Intriguing Points From Today's 52-Week Lows: Sanofi ...

Why Avalo Therapeutics Surged 32%; Here Are 111 Biggest Movers From Yesterday
10 Aug, 2022 FinancialContent

Gainers AeroClean Technologies, Inc. (NASDAQ: AERC) gained 60.1% to settle at $7.27 on Tuesday after the company was granted US ...

Dow Drops Over 100 Points; Verona Pharma Shares Jump
09 Aug, 2022 FinancialContent

U.S. stocks traded lower toward the end of trading, with the Dow Jones dropping more than 100 points on Tuesday. The Dow traded down ...

12 Health Care Stocks Moving In Tuesday's Intraday Session
09 Aug, 2022 FinancialContent

Gainers Verona Pharma (NASDAQ:VRNA) stock moved upwards by 35.8% to $9.44 during Tuesday's regular session. As of ...

Why Verona Pharma Is Trading Higher By Around 84%, Here Are 85 Stocks Moving In Tuesday's Mid-Day Session
09 Aug, 2022 FinancialContent

Gainers Verona Pharma plc (NASDAQ: VRNA) shares jumped 83.6% to $12.70 after the company announced ensifentrine met its primary ...

Nasdaq Tumbles 1.5%; BBQ Holdings Shares Spike Higher
09 Aug, 2022 FinancialContent

U.S. stocks traded lower midway through trading, with the Nasdaq dropping around 1.5% on Tuesday. The Dow traded down 0.12% to ...

Stocks That Hit 52-Week Lows On Tuesday
09 Aug, 2022 FinancialContent

On Tuesday, 73 companies hit new 52-week lows. 52-Week Low Highlights: Intel (NASDAQ:INTC) was the largest, in terms ...

Aytu BioPharma Announces Pricing of Public Offering
09 Aug, 2022 FinancialContent

ENGLEWOOD, CO / ACCESSWIRE / August 9, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the pricing of its underwritten public offering of (i) 21,505,814 shares of its common stock, and, in lieu of common stock to certain investors that so chose, pre-funded warrants to purchase 1,750,000 shares of its common stock, and (ii) accompanying warrants (the "Common Warrants") to purchase 23,255,814 shares of its common stock (the "Offering"). The shares of common stock (or pre-funded warrants) and the accompanying Common Warrants will be issued separately but can only be purchased together in this Offering. The combined public offering price for each share of common stock and accompanying Common Warrant is $0.43, and the combined offering price for each pre-funded warrant and accompanying Common Warrant is $0.429, which equals the public offering price per share of the common stock and accompanying Common Warrant, less the $0.001 per share exercise price of each pre-funded warrant. The aggregate gross proceeds from the Offering are expected to be approximately $10 million, before deducting the underwriting discounts and commissions and estimated offering expenses payable by Aytu. All of the securities in the Offering will be sold by Aytu. The Offering is expected to close on August 11, 2022, subject to the satisfaction of customary closing conditions.

Biotech Daily: Regulatory Setback For CorMedix, Mersana & GSK In Cancer Pact, BARDA Funding For Opioid Overdose Hopeful
09 Aug, 2022 FinancialContent

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Mersana, GSK Ink $1.36B ...

12 Health Care Stocks Moving In Tuesday's Pre-Market Session
09 Aug, 2022 FinancialContent

Gainers Verona Pharma (NASDAQ:VRNA) stock increased by 71.8% to $11.94 during Tuesday's pre-market session. The ...

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
09 Aug, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips We're starting off Tuesday with a breakdown of the biggest pre-market stock movers traders will want to keep an eye on today! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday appeared first on InvestorPlace. More From InvestorPlace Buy This $5 Stock BEFORE This Apple Project Goes Live The Best $1 Investment You Can Make Today Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air” It doesn’t matter if you have $500 or $5 million. Do this now.

Why Is BIMI International Medical Higher By Around 70%: Here Are 38 Stocks Moving Premarket
09 Aug, 2022 FinancialContent

Gainers BIMI International Medical Inc. (NASDAQ: BIMI) shares rose 69.6% to $1.04 in pre-market trading after Fnu Oudom reported a ...

12 Health Care Stocks Moving In Monday's After-Market Session
08 Aug, 2022 FinancialContent

Gainers BIMI Intl Medical (NASDAQ:BIMI) stock moved upwards by 90.8% to $1.17 during Monday's after-market session. ...

Aytu BioPharma Announces Launch of Public Offering
08 Aug, 2022 FinancialContent

ENGLEWOOD, CO / ACCESSWIRE / August 8, 2022 / Aytu BioPharma, Inc. (the "Company" or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the launch of an underwritten public offering of shares of its common stock or, in lieu of common stock to certain investors that so choose, pre-funded warrants to purchase shares of its common stock, and accompanying warrants to purchase its common stock (the "Offering"). All of the securities in the Offering will be sold by Aytu. The Offering is subject to market and other conditions, and there can be no assurance as to whether or when the Offering may be completed or as to the actual size or terms of the Offering.

Aytu BioPharma to Participate in the Canaccord Genuity 42nd Annual Growth Conference
26 Jul, 2022 FinancialContent

ENGLEWOOD, CO / ACCESSWIRE / July 26, 2022 / Aytu BioPharma, Inc. (the "Company") (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that Chief Executive Officer Josh Disbrow and Chief Financial Officer Mark Oki will participate in the Canaccord Genuity 42nd Annual Growth Conference being held August 8-11, 2022 at the InterContinental Hotel in Boston, MA.

Recap of Wednesday's Biotech Catalysts - End of The Day Summary
20 Jul, 2022 FinancialContent

Merck (NYSE: MRK) announced that the Phase 3 KEYNOTE-412 trial evaluating KEYTRUDA (pembrolizumab), Merck's ...

Aytu BioPharma Commences Late-Stage Genetic Disorder Study
20 Jul, 2022 FinancialContent

Aytu BioPharma (NASDAQ: AYTU) has initiated the global Phase 3 PREVEnt clinical trial of Enzastaurin (AR101) for the treatment of ...

Aytu BioPharma Announces Initiation of the AR101 PREVEnt Trial for the Treatment of Vascular Ehlers-Danlos Syndrome
20 Jul, 2022 FinancialContent

ENGLEWOOD, CO / ACCESSWIRE / July 20, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the initiation of the global Phase 3 PREVEnt (Prevention of Ruptures with Enzastaurin for Vascular Ehlers-Danlos Syndrome) clinical trial of enzastaurin (AR101) for the treatment of patients with COL3A1-positive Vascular Ehlers-Danlos Syndrome (VEDS). VEDS is a rare genetic disorder typically diagnosed in childhood and characterized by arterial aneurysm, dissection and rupture, bowel rupture and rupture of the gravid uterus. The company has begun patient identification and study site contracting and has received regulatory clearance to initiate this registrational study in the United States and numerous countries in Europe.

12 Health Care Stocks Moving In Wednesday's Pre-Market Session
06 Jul, 2022 FinancialContent

Gainers SCWorx (NASDAQ:WORX) shares increased by 38.7% to $0.86 during Wednesday's pre-market session. The ...

Akerna Shares Dip 53%, Here's 78 Biggest Movers From Yesterday
01 Jul, 2022 FinancialContent

Gainers Revelation Biosciences, Inc. (NASDAQ: REVB) surged 77.4% to close at $1.11 on Thursday after jumping 27% on Wednesday. ...

Aytu BioPharma Announces the Appointment of Vivian Liu to the Company's Board of Directors
29 Jun, 2022 FinancialContent

ENGLEWOOD, CO / ACCESSWIRE / June 29, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced the appointment of Vivian Liu to the company's board of directors, effective July 1, 2022. Ms. Liu will serve as an independent director and as a member of the Nominating & Corporate Governance Committee.

Aytu BioPharma to Participate in the Lytham Partners Summer 2022 Investor Conference
13 Jun, 2022 FinancialContent

ENGLEWOOD, CO / ACCESSWIRE / June 13, 2022 / Aytu BioPharma, Inc. (NASDAQ:AYTU), a pharmaceutical company focused on developing and commercializing novel therapeutics, today announced that the company will be participating in the Lytham Partners Summer 2022 Investor Conference taking place virtually on June 21-22, 2022.

Aytu BioPharma Plans To Divest / Discontinue Non Core Assets
17 May, 2022 FinancialContent

Aytu BioPharma Inc(NASDAQ: AYTU)will divest or discontinuenon-core, unprofitable products, including Cefaclor, ...

Aytu BioPharma: Q3 Earnings Insights
16 May, 2022 FinancialContent

Aytu BioPharma (NASDAQ:AYTU) reported its Q3 earnings results on Monday, May 16, 2022 at 04:02 PM. Here's what investors need to know ...

Aytu BioPharma Reports Third Quarter 2022 Financial Results and Outlines Key Strategic Priorities
16 May, 2022 FinancialContent

Quarterly Net Revenue Increased 79% Year-Over-Year to $24.2 Million, the Highest Revenue in Company History

Aytu BioPharma Announces Positive Preclinical Data in Ventilator-Associated Pneumonia with its Novel, Proprietary Healight(TM) Delivery Technology
25 Apr, 2022 FinancialContent

Preclinical Proof-of-Concept Study Demonstrates Effectiveness of Healight in Delaying Time to Development of Ventilator-Associated Pneumonia

Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
25 Apr, 2022 FinancialContent

InvestorPlace - Stock Market News, Stock Advice & Trading Tips Another day of investing awaits for traders as we start it off with a breakdown of the biggest pre-market stock movers for Monday! The post Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS It doesn’t matter if you have $500 in savings or $5 million. Do this now. Get in Now on Tiny $3 ‘Forever Battery’ Stock Early Bitcoin Millionaire Reveals His Next Big Crypto Trade “On Air”

12 Health Care Stocks Moving In Friday's After-Market Session
22 Apr, 2022 FinancialContent

Gainers TC BioPharm (Holdings) (NASDAQ:TCBP) stock moved upwards by 16.8% to $1.32 during Friday's after-market session. The ...

Aytu Biopharma, Inc (AYTU) is a NASDAQ Common Stock listed in , ,

970x250